Clinical Trial Update: MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update on IMU-838 (IMU-838) evaluating efficacy and safety in Relapsing-Remitting Multiple Sclerosis (RRMS) called EMPhASIS.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• IMU-838 (IMU-838)

Snippet

Sponsor: Immunic AG | Conditions: Relapsing-Remitting Multiple Sclerosis (RRMS) | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-07-23